William F Anderson1, Ruth M Pfeiffer1, Jan Wohlfahrt2, Bent Ejlertsen3, Maj-Britt Jensen3, Niels Kroman4. 1. DHHS/NIH/National Cancer Institute/Division of Cancer Epidemiology and Genetics/Biostatistics Branch, Bethesda, MD, USA. 2. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. 3. Danish Breast Cancer Group (DBCG), Copenhagen, Denmark. 4. Department of Breast Surgery, Rigshopitalet, Copenhagen, Denmark.
Abstract
Background: Associations of reproductive history with breast cancer risk differ by oestrogen receptor (ER±) status and possibly by the joint expression of ER and the human epidermal growth factor receptor-2 (ER±/HER2±). However, large sample sizes are needed to establish ER-specific risks by HER2± expression. Methods: We linked a cancer registry covering nearly 95% of the primary breast cancer diagnoses in Denmark with a research parity database to assess associations for parity, number of live births and age at first live birth (AFLB) with receptor-specific risk. Relative risks (RRs) for associations were estimated with Poisson regression models. Results: With nearly 31 million women-years of follow-up, 45 786 Danish women aged 20-84 years developed invasive breast cancer during 1992-2011. ER± expression was available for the entire study period and HER2± after 2006. Of the breast cancers with known ER expression, 79% were ER+. Most breast cancers with known ER and HER2 were HER2- (90% of ER+ cancers and 65% of ER- cancers). RRs differed by ER± expression for all reproductive variables ( p -homogeneity < 0.001). Associations were stronger for ER+ than ER- cancers and for those diagnosed before age 50. Parity and early [not later] AFLB showed a protective association with ER+/HER2- and risk association with ER-/HER2- cancers. Conclusion: Associations of reproductive history with breast cancer risk varied among Danish women by ER± and ER±/HER2± expression and age-at-diagnosis, consistent with receptor-specific and age-related etiological heterogeneity. Further stratification by HER2 status demonstrated dual (or opposite) effects for ER+/HER2- and ER-/HER2- cancers. Published by Oxford University Press on behalf of the International Epidemiological Association 2016. This work is written by US Government employees and is in the public domain in the US.
Background: Associations of reproductive history with breast cancer risk differ by oestrogen receptor (ER±) status and possibly by the joint expression of ER and the humanepidermal growth factor receptor-2 (ER±/HER2±). However, large sample sizes are needed to establish ER-specific risks by HER2± expression. Methods: We linked a cancer registry covering nearly 95% of the primary breast cancer diagnoses in Denmark with a research parity database to assess associations for parity, number of live births and age at first live birth (AFLB) with receptor-specific risk. Relative risks (RRs) for associations were estimated with Poisson regression models. Results: With nearly 31 million women-years of follow-up, 45 786 Danish women aged 20-84 years developed invasive breast cancer during 1992-2011. ER± expression was available for the entire study period and HER2± after 2006. Of the breast cancers with known ER expression, 79% were ER+. Most breast cancers with known ER and HER2 were HER2- (90% of ER+ cancers and 65% of ER- cancers). RRs differed by ER± expression for all reproductive variables ( p -homogeneity < 0.001). Associations were stronger for ER+ than ER- cancers and for those diagnosed before age 50. Parity and early [not later] AFLB showed a protective association with ER+/HER2- and risk association with ER-/HER2- cancers. Conclusion: Associations of reproductive history with breast cancer risk varied among Danish women by ER± and ER±/HER2± expression and age-at-diagnosis, consistent with receptor-specific and age-related etiological heterogeneity. Further stratification by HER2 status demonstrated dual (or opposite) effects for ER+/HER2- and ER-/HER2- cancers. Published by Oxford University Press on behalf of the International Epidemiological Association 2016. This work is written by US Government employees and is in the public domain in the US.
Entities:
Keywords:
breast cancer aetiology; breast cancer subtype; human epidermal growth factor receptor-2; oestrogen receptor; reproductive history
Authors: William F Anderson; Philip S Rosenberg; Aleix Prat; Charles M Perou; Mark E Sherman Journal: J Natl Cancer Inst Date: 2014-08-12 Impact factor: 13.506
Authors: M Melbye; J Wohlfahrt; J H Olsen; M Frisch; T Westergaard; K Helweg-Larsen; P K Andersen Journal: N Engl J Med Date: 1997-01-09 Impact factor: 91.245
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Amber N Hurson; Mustapha Abubakar; Alina M Hamilton; Kathleen Conway; Katherine A Hoadley; Michael I Love; Andrew F Olshan; Charles M Perou; Montserrat Garcia-Closas; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-04 Impact factor: 4.090
Authors: Hyuna Sung; Beena C R Devi; Tieng S Tang; Philip S Rosenberg; William F Anderson; Xiaohong R Yang Journal: Int J Cancer Date: 2019-12-23 Impact factor: 7.316
Authors: Dhirendra Govender; Xiaohong R Yang; Shahin Sayed; Shaoqi Fan; Zahir Moloo; Ronald Wasike; Peter Bird; Mansoor Saleh; Asim Jamal Shaikh; Jonine D Figueroa; Richard Naidoo; Francis W Makokha; Kevin Gardner; Raymond Oigara; Faith Wambui Njoroge; Pumza Magangane; Miriam Mutebi; Rajendra Chauhan; Sitna Mwanzi Journal: Breast Cancer Res Date: 2021-06-26 Impact factor: 6.466